FundedIQ
Biotechnology

Tacalyx: Funding, Investors & Team (Sep 2026)

Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is dedicated to researching Tumor-Associated Carbohydrate Antigens (TACAs) as a potential new target for cancer therapy. TACAs are expressed specifically in tumors due to abnormal glycosylation, and contribute to processes like metastasis, angiogenesis, and immune suppression. Tacalyx utilizes advanced carbohydrate synthesis technology to create pure TACA structures, which are then used to develop antibodies for innovative cancer treatments.

www.tacalyx.com LinkedIn Berlin, Germany 1-10 employees
Biotechnology Health Care Life Science Therapeutics B2B
Total raised
$7.5M
Rounds
2
Latest
Seed
Apr 2026

Tacalyx has raised $7.5M across 2 funding rounds on record, the most recent a Seed announced in Apr 2026.

Tacalyx Company Profile and Key Stats

Total funding raised
$7.5M
across 2 rounds on record
Funding rounds on record
2
1 with no disclosed amount
Latest funding round
Seed
Apr 2026
Employees
1-10
reported band
Headquarters
Berlin, Germany

Latest funding round on record: Apr 2026.

Tacalyx Funding Rounds

Date
Round
Amount
Seed
Undisclosed
Seed
$7.5M

1 of 2 rounds was announced without a disclosed amount and is excluded from the total.

Tacalyx raised $7.5M in a Seed announced in Jun 2024.

1.8 years later, a Seed was announced in Apr 2026 with no disclosed amount.

Tacalyx Founders and Leadership Team

Name
Role
Contact
Jean Engela
Founder
Peter Sondermann
Founder
Locked

Contact details for the Tacalyx team: 1 of 2 have an email address on file.

Start 14-day free trial →

Tacalyx Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
1,812
$6.5M
16,485
$3.1M

Funded Startups Like Tacalyx in Biotechnology and Berlin

Companies Similar to Tacalyx

Tacalyx Funding FAQs

What does Tacalyx do?

Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is dedicated to researching Tumor-Associated Carbohydrate Antigens (TACAs) as a potential new target for cancer therapy. TACAs are expressed specifically in tumors due to abnormal glycosylation, and contribute to processes like metastasis, angiogenesis, and immune suppression. Tacalyx utilizes advanced carbohydrate synthesis technology to create pure TACA structures, which are then used to develop antibodies for innovative cancer treatments.

How much funding has Tacalyx raised?

Tacalyx has raised $7.5M across 2 rounds on record.

When did Tacalyx last raise funding?

Tacalyx's most recent funding round on record was announced in Apr 2026. The amount was not disclosed.

Who founded Tacalyx?

FundedIQ lists Jean Engela (Founder), Peter Sondermann (Founder) at Tacalyx.

Where is Tacalyx headquartered?

Tacalyx is based in Berlin, Germany.

How many employees does Tacalyx have?

Tacalyx is in the 1-10 employee band.

About FundedIQ's Tacalyx Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tacalyx is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.